ClinicalTrials.gg
Active, not recruitingNCT06770933Updated Oct 2, 2026

A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01

A Phase 2 interventional study of VX-01 and Placebo in Diabetic Retinopathy and NPDR - Non Proliferative Diabetic Retinopathy, sponsored by Vantage Biosciences Ltd. Active, not recruiting at 27 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Vantage Biosciences Ltd · Phase 2, Interventional, and Treatment

How we know

Updated Oct 2, 2026Now Active, not recruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 267 studies in Diabetic Retinopathy with a site in United States — 36 open to participants now, 54 under way, 6 of them phase 3. Diabetic Retinopathy · United States.

Planned enrollment
87th of 196
100 · median 72
Started
2025
with 11 others
Phase 2
52 of 267
3 open now
Primary completion
2027-07
later than 27 of 52 live
Registered
238th of 267
by date

Among the 267 studies in Diabetic Retinopathy with a site in United States, this one is the 87th largest by planned enrollment of the 196 interventional ones that give a count, is one of 12 that started in 2025, is one of 52 in phase 2, reaches primary completion later than 27 of the 52 other live ones, and was the 238th registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

36 of the 267 studies in Diabetic Retinopathy with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 267 studies in Diabetic Retinopathy with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of VX-01 as stand-alone treatment for Diabetic Retinopathy of Non-Proliferative Type (NPDR).

The primary objective of the study is to evaluate the efficacy of daily oral doses of VX-01 versus placebo following 52 weeks of treatment.

Read the detailed description

This is a Phase 2, multi-center, double-masked, randomized, placebo-controlled, parallel group study to evaluate the efficacy of oral doses of VX-01 in subjects with moderate to severe NPDR, without CI-DME.

Approximately 100 male and female subjects aged ≥ 18 years with a documented diagnosis of Type 1 Diabetic Mellitus or Type 2 Diabetic Mellitus with moderate to severe NPDR (without CI-DME) will be enrolled, if they meet all the eligibility criteria for the study.

Subjects will be randomized 1:1 to 1 of 2 study cohorts:

  • Cohort 1 (n = 50): VX-01 (film-coated tablets, 150 mg administered BID)
  • Cohort 2 (n = 50): Placebo (film-coated tablets, administered BID)

Subjects will be stratified by the presence or absence of proliferative diabetic retinopathy (PDR) and by glycated hemoglobin (HbA1c) of ≥ 8.5% or \< 8.5% at Screening. All subjects will take 1 tablet of VX-01 or placebo BID for 52 consecutive weeks. All subjects will be followed for 12 weeks after completion of treatment at Week 52.

The Sponsor, study site staff, monitors, personnel, and subjects will be masked to treatment assignment during the entirety of the study.

03

Conditions studied

  • Diabetic Retinopathy
  • NPDR - Non Proliferative Diabetic Retinopathy

Browse trials for

Keywords

  • NPDR
  • Diabetic Retinopathy
  • AOC3
  • VAP-1
  • SSAO
  • VAP1
  • Amine Oxidase Copper containing 3
  • Amine Oxidase
  • HPAO
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must be obtained from the subject prior to any study-related procedures.
  • Subject must be aged > 18 years at the time of Screening.
  • Subject must have a (BMI) of between 18 and 40 kg/m2, inclusive.
  • Subject has a documented diagnosis of T1DM or T2DM.
  • Subject has moderate to severe NPDR, as determined by a Central Reading Centre (CRC) using DRSS in at least one eye
  • Subject must have clear ocular media and be able to undergo adequate pupil dilation to allow adequate fundus imaging of both eyes.
  • Female subject must be either:

    1. Of non-: or documented surgically sterile post hysterectomy (at least 1 month prior to Screening)
    2. Or, if of childbearing potential, must have a negative serum pregnancy test at Screening and must use 2 acceptable forms of , starting at Screening and throughout the study period and for 28 days after the final IP administration.
  • Female subject must not be breastfeeding at Screening or during the study period, and for 28 days after the final IP administration.
  • Male subject must be surgically sterile (> 30 days since vasectomy with no viable sperm), or if engaged in sexual relations with a female of childbearing potential, the couple should agree to use 2 acceptable contraceptive methods from Screening, during the study, and for 28 days after last IP administration.

Female subject must not donate ova or male subject must not donate sperm starting at Screening and throughout the study period, and for 28 days after the final IP administration.

  • Subject must have Best Corrected Visual Acuity (BCVA) assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) protocol letters score of ≥ 70 letters in study eye, and ≥ 20 letters in the non-qualified fellow eye.
  • Subject must have the ability, in the opinion of the Investigator, and willingness to return for all scheduled visits and perform all assessments.
  • Subject agrees not to participate in another interventional study after signing the informed consent and until the End of Study (EOS) visit has been completed.

Exclusion criteria

Exclusion Criteria:

Ophthalmic:

  • Presence of CI-DME (with central subfield thickness [CST] measured greater than 325 μm on spectral domain optical coherence tomography [SD-OCT]) threatening the center of the macula (within 1,000 μm of the foveal center) in either eye, or presence of DME requiring treatment.
  • Presence of moderate to high-risk PDR (DRSS level 65 or higher).
  • Any prior treatment (in either eye) with:

    1. Focal or grid laser photocoagulation within the past 6 months prior to Screening or pan-retinal photocoagulation (PRP) at any time.
    2. Systemic or intravitreal anti-vascular endothelial growth factor (VEGF) agents within the last 12 months prior to Screening.
    3. Intraocular, sub-tenon or periocular , including triamcinolone and dexamethasone implant within the last 6 months, or suprachoroidal triamcinolone within the last 3 months prior to Screening.
    4. Fluocinolone implant within the last 3 years prior to Screening.
    5. Prior treatment for NPDR with any other treatment which is not labelled for NPDR within 1 year prior to Screening (e.g., calcium dobesilate, fibrate medication).
    6. Vitrectomy at any timepoint prior to Screening.
    7. Yttrium-Aluminium-Granate (YAG) capsulotomy within 3 months prior to Screening.
  • Active uveitis, vitritis, or infection in either eye including infectious conjunctivitis, keratitis, scleritis, or endophthalmitis.
  • History of corneal transplant and/or vitrectomy or any other ocular incisional surgery in either eye (e.g., shunt surgery). Note: Subjects who have had cataract or refractive surgery in either that was more than 3 months prior to Screening may be permitted at the discretion of the Investigator.
  • Uncontrolled glaucoma, as evidenced by intraocular pressure (IOP) > 25 mmHg despite up to 4 glaucoma medications, or evidence of glaucomatous visual field loss or has advanced glaucoma (e.g., prior shunt surgery) in either eye.
  • ocular disease in either eye that in the opinion of the Investigator would preclude participation in the study.
  • Presence of macular or retinal vascular disease including DME and/or retinopathy from causes other than diabetes, age-related macular degeneration, pattern dystrophy, choroidal neovascularisation of any cause, retinal vein occlusion, retinal artery occlusion in either eye.
  • History of retinal detachment or full-thickness macular hole post intraocular surgery in either eye, or idiopathic or uveitis in either eye.
  • Any other ocular disease that may cause substantial reduction in BCVA.

Systemic:

  • Known, suspected or to IP.
  • Uncontrolled diabetes mellitus with of ≥ 12%.
  • Initiation of treatment with glucagon-like peptide-1 (GLP-1) modulators for glycaemic control and other indications within the last 3 months prior to Screening.
  • Initiation of intensive insulin treatment (a pump or multiple daily injections) within 3 months prior to Screening or plans to do so in the next 3 months.
  • Current use of coumarin anticoagulants (Coumadin/Warfarin).
  • On dialysis or an estimated (eGFR) of \< 30 mL/min/1.73m2 as per CKD-EPI evaluation at Screening. (Active Diabetic Ketoacidosis or Hyperglycemic Hyperosmolar Nonketotic State).
  • Hypertension with resting diastolic blood pressure (BP) > 100 mmHg or systolic BP > 180 mmHg on 2 consecutive measurements at least 5 minutes apart. Note: If the result is out of range, the assessment may be repeated once prior to randomisation for confirmation.
  • Resting heart rate outside the specified range (50 to 110 beats per minute). Note: If the result is out of range, the assessment may be repeated once prior to randomisation for confirmation.
  • History of chronic liver disease or presence of elevated (defined as > 3 × ) (ALT) and aspartate aminotransferase (AST) consistent with such diagnosis.
  • Known to be or receiving immunosuppressive therapy. Note: Subjects receiving low dose corticosteroids may be eligible, at the discretion of the Investigator.
  • Currently receiving treatment with a strong inhibitor of the P-glycoprotein transporter (see Section 6.4.2), which may interfere with the IP.
  • History of allergy to fluorescein.
  • Any disease or medical condition that in the opinion of the Investigator would interfere with the study, prevent the subject from successfully participating in the study, or which might confound the study results.
  • Participation in any study within 30 days prior to Screening or planning to participate in any other investigational drug or device clinical trials within 30 days of study completion.
  • History of blood transfusion or severe blood loss within 3 months prior to Screening, known hemoglobinopathy, and severe anaemia.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    VX-01

    Cohort 1 will include 50 subjects who will be randomized to take investigational drug VX-01 (film-coated tablets) at dose of 150 mg, administered BID.

    Drug: VX-01

  • Placebo comparator
    Placebo

    Cohort 2 will include 50 subjects who will be randomized to receive the placebo drug (film-coated tablets), that will be administered BID.

    Drug: Placebo

Interventions

  • DrugVX-01

    There is no physical difference in VX-01 and the placebo. The only difference lies in active ingredient found in VX-01, which is the compound that will be evaluated in the course of this study.

  • DrugPlacebo

    Placebo will be supplied as a tablet identical to test drug but without VX-01. Placebo packaging will be identical to IP in order to keep study personnel and subjects masked.

06

What researchers measure

Primary outcomes

  1. Evaluate the efficacy of oral doses of VX-01 in subjects compared to placebo following 1 year of treatment.

    The endpoint of this objective is the proportion of subjects who do not develop a worsening from Baseline in binocular ETDRS DRSS at Week 52. The diabetic retinopathy severity scale (DRSS) is a scale healthcare professionals use to measure the severity and progression of a person's diabetic retinopathy. The main DRSS is the Early Treatment Diabetic Retinopathy Study (ETDRS) scale which will be used in this study.

    Time frame: From enrollment to the end of treatment at week 52

Secondary outcomes

  1. To evaluate the efficacy of VX-01 in subjects with moderate to severe NPDR without CI-DME by determining the overall change from Baseline in BCVA letter scores.

    Endpoint measurement of this objective will be improvement in Best Corrected Visual Acuity (BCVA), i.e. higher scoring at end of treatment compared to enrollment (baseline).

    Time frame: From enrollment to the end of treatment at week 52

  2. To evaluate the efficacy of VX-01 in subjects with moderate to severe NPDR without CI-DME by determining the overall change from Baseline in the ETDRS DRSS scores.

    Endpoint measurement of this objective will be improvement in the Early Treatment Diabetic Retinopathy score (ETDRS), i.e. higher score at end of treatment compared to enrollment (baseline measure)

    Time frame: From enrollment to the end of treatment at week 52

  3. Incidence of Treatment-Emergent Adverse Events (TEAEs) when taking multiple oral doses of VX-01.

    Endpoint measurement of this objective will include assessing the nature, frequency, and severity of systemic and ocular TEAEs across the duration of the study. A lower number of TEAEs would point towards a better safety and tolerability profile of VX-01

    Time frame: From enrollment to the end of treatment at week 52

  4. Number of subjects developing moderate to high risk proliferative diabetic retinopathy

    Measurement of proportion of subjects who develop moderate to high-risk proliferative diabetic retinopathy in either eye at Week 24 and also at Week 52 will be quantified. This will aid in understanding the safety of VX-01.

    Time frame: From enrollment to the end of treatment at week 52

07

Study locations

27 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jul 2027, 29 months after the start.

Of 30 industry-sponsored phase 2 interventional studies under Diabetic Retinopathy, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 37. This study's planned 29 months is close to that.

Counting every sponsor, half of 43 studies reached it within 31 months; a quarter within 17 and three quarters within 37.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Mar 2027 → Jul 2027 and completion Mar 2027 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2024
First posted
Jan 13, 2025
StartActual
Feb 11, 2025
Primary completionEst.
Jul 2027was Mar 2027
CompletionEst.
Oct 2027was Mar 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 2, 2026
Sites
3 sites added, 2 sites removed
Show 3 added (2 United States, 1 South Korea)
  • Southeast Retina Center · Augusta, United States
  • Sterling Vision, PC · Eugene, United States
  • Samsung Medical Center · Seoul, South Korea
Show 2 removed
  • Retina Associates · Elmhurst, United States
  • Samsung Medical Center · Seoul 81, Korea, Republic of
Oct 2, 2026
Primary completion
Mar 2027→Jul 2027
Oct 2, 2026
Study completion
Mar 2027→Oct 2027
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Recruiting→Active, not recruiting
    3 sites added, 2 sites removed
    Show 3 added (2 United States, 1 South Korea)
    • Southeast Retina Center · Augusta, United States
    • Sterling Vision, PC · Eugene, United States
    • Samsung Medical Center · Seoul, South Korea
    Show 2 removed
    • Retina Associates · Elmhurst, United States
    • Samsung Medical Center · Seoul 81, Korea, Republic of
    Primary completion Mar 2027→Jul 2027
    Study completion Mar 2027→Oct 2027
    + 5 other changes: index terms, verification date, registry dates, oversight details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06770933
Lead sponsor
Vantage Biosciences Ltd
Collaborators
Vantage Biosciences Australia Pty Ltd
Responsible party
Sponsor
First posted
Jan 13, 2025
Start date
Feb 11, 2025
Primary completion
Jul 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Oct 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion